arrow
J

John Barnes

Centers for Disease Control and Prevention
H指数:48
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Supporting molecular detection of A(H5N1) through development and characterization of RNA reference materials

通过RNA参考材料的开发与表征支持A(H5N1)的分子检测

2026-07-220
OAAI
Development and Characterization of Candidate Vaccine Viruses against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response

针对高致病性禽流感A(H5)病毒快速大流行应对的候选疫苗病毒的开发与表征

2026-02-280
OA
Influenza mRNA vaccine reduces pathogenicity and transmission of A(H5N1) virus in a ferret model

流感mRNA疫苗在雪貂模型中降低了A(H5N1)病毒致病性和传播性

2025-11-290
OAAI
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus
2024-12-180
PRE
Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years: Results and Experience From a Randomized, Double-Blind Trial

在18-64岁的成年人中,四价重组流感疫苗与基于鸡蛋的灭活流感疫苗的相对有效性和免疫原性: 一项随机,双盲试验的结果和经验

2024-09-261
OA
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States
2024-09-254
OA
Characterization of Avian Influenza Viruses Detected in Kenyan Live Bird Markets and Wild Bird Habitats Reveal Genetically Diverse Subtypes and High Proportion of A(H9N2), 2018-2020
2024-09-050
OAAI
Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
2024-06-230
OA
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves

在整个Delta到Omicron波中,美国循环和新兴SARS-CoV-2变体的抗原表征

2024-05-074
OAAI
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants( vol 28 , pg 1083 , 2022)
2023-11-091
OAAI
Risk for Infection in Humans after Exposure to Birds Infected with Highly Pathogenic Avian Influenza A(H5N1) Virus, United States, 2022
2023-06-0114
OAAI
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
2022-07-2733
OAAI
SARS-CoV-2 Delta-Omicron Recombinant Viruses, United States
2022-07-0123
OAAI